The RASSF1A tumor suppressor

Journal of Cell Science

Volumn 120, Issue 18, 2007, Pages 3163-3172

  Donninger, Howard ^a   Vos, Michele D ^b   Clark, Geoffrey J ^a  

^a University of Louisville School of Medicine   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epigenetic; Ras; RASSF1A; Tumor suppressor

Indexed keywords

K RAS PROTEIN; PROTEIN P120; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MOTILITY; COLORECTAL CANCER; ENZYME ACTIVITY; EPENDYMOMA; ESOPHAGUS CANCER; GENE DELETION; GENE INACTIVATION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOTHESIS; KIDNEY CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MELANOMA; METHYLATION; NASOPHARYNX CANCER; NEPHROBLASTOMA; NEUROBLASTOMA; NOTE; OVARY CANCER; PANCREAS CANCER; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; RETINOBLASTOMA; RHABDOMYOSARCOMA; SEMINOMA; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; UTERINE CERVIX CARCINOMA;

ANIMALS; APOPTOSIS; CELL CYCLE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE DELETION; GENE SILENCING; HUMANS; NEOPLASMS; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 35548987430     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.010389     Document Type: Note

References (134)

1. Agathanggelou, A., Honorio, S., Macartney, D. F., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A. et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 20, 1509-1518.
2. Agathanggelou, A., Bièche, I., Ahmed-Choudhury, J., Nicke, B., Dammann, R., Baksh, S., Gao, B., Minna, J. D., Downward, J., Maher, E. R. et al. (2003). Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res. 63, 5344-5351.
3. Agathanggelou, A., Cooper, W. N. and Latif, F. (2005). Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65, 3497-3508.
4. E4F to the cyclin A2 promoter. Cancer Res. 65, 2690-2697.
5. Akino, K., Toyota, M., Suzuki, H., Mita, H., Sasaki, Y., Ohe-Toyota, M, Issa, J. P., Hinoda, Y., Imai, K. and Tokino, T. (2005). The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129, 156-169.
6. Allen, N. P., Donninger, H., Vos, M. D., Eckfeld, K., Hesson, L., Gorden, L., Birrer, M. J., Latif, F. and Clark, G. J. (2007). RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene doi:10.1038/sj.onc.1210440.
7. 2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J. Biol. Chem. 279, 31318-31328.
8. Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P., Voutilainen R., Dahia, P. et al. (2001). RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 20, 7573-7577.
9. Avruch, J., Praskova, M., Ortiz-Vega, S., Liu, M. and Zhang, X. F. (2005). Norel and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Meth. Enzymol. 407, 290-310.
10. Baksh, S., Tommasi, S., Fenton, S., Yu, V. C., Martins, M., Pfeifer, G. P., Latif, F., Downward, J. and Neel, B. G. (2005). The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol. Cell 18, 637-650.
11. Burbee, D. G., Forgacs, E., Zöchbauer-Müller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S. et al. (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93, 691-699.
12. Calvisi, D. F, Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J.-S., Factor, V. M. and Thorgeirsson, S. S. (2006). Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130, 1117-1128.
13. Chan, M. W., Chan, L. W., Tang, N. L., Lo, K. W., Tong, J. H., Chan, A. W., Cheung, H. Y., Wong, W. S., Chan, P. S., Lai, F. M. et al. (2003). Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int. J. Cancer 104, 611-616.
14. Chen, H., Suzuki, M., Nakamura, Y., Ohira, M, Ando, S., Iida, T., Nakajima, T., Nakagawara, A. and Kimura, H. (2006). Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol. Rep. 15, 1281-1285.
15. Chen, J., Lui, W. O., Vos, M. D., Clark, G. J., Takahashi, M., Schoumans, J., Khoo, S. K., Petillo, D., Lavery, T., Sugimura, J. et al. (2003). The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 4, 405-413.
16. Cheung, W. L., Ajiro, K., Samejima, K., Kloc, M., Cheung, P, Mizzen, C. A., Beeser, A., Etkin, L. D., Chernoff, J., Earnshaw, W. C. et al. (2003). Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113, 507-517.
17. Chow, L. S., Lam, C. W., Chan, S. Y, Tsao, S. W., To, K. F., Tong, S. F., Hung, W. K., Dammann, R., Huang, D. P. and Lo, K. W. (2006). Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene 25, 310-316.
18. Cohen, Y., Singer, G., Lavie, O., Dong, S. M., Beller, U. and Sidransky, D. (2003). The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin. Cancer Res. 9, 2981-2984.
19. Cox, A. D. and Der, C. J. (2003). The dark side of Ras: regulation of apoptosis. Oncogene 22, 8999-9006.
20. Dallol, A., Agathanggelou, A., Fenton, S. L., Ahmed-Choudhury, J., Hesson, L., Vos, M. D., Clark, G. J., Downward, J., Maher, E. R. and Latif, F. (2004). RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 64, 4112-4116.
21. Dallol, A., Agathanggelou, A., Tommasi, S., Pfeifer, G. P., Maher, E. R. and Latif, F. (2005). Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res. 65, 7653-7659.
22. Dallol, A, Cooper, W. N., Al-Mulla, F., Agathanggelou, A., Maher, E. R. and Latif, F. (2007). Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. Cancer Res. 67, 492-500.
23. Dammann, R., Li, C., Yoon, J.-H., Chin, F. L., Bates, S. and Pfeifer, G. P. (2000). Epigenetic inactivation of a RAS association domain family protein from lung tumour suppressor locus 3p21.3. Nat. Genet. 25, 315-319.
24. Dammann, R., Schagdarsurengin, U., Strunnikova, M., Rastetter, M., Seidel, C., Liu, L., Tommasi, S. and Pfeifer, G. P. (2003). Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol. Histopathol. 18, 665-677.
25. Dong, S. M., Sun, D. I., Benoit, N. E., Kuzmin, I., Lerman, M. I. and Sidransky, D. (2003). Epigenetic inactivation of RASSF1A in head and neck cancer. Clin. Cancer Res. 9, 3635-3640.
26. Downward, J. (1998). Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 8, 49-54.
27. Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F.-M., Angeloni, D., Zbar, B., Lerman, M. I., Stanbridge, E. J., Minna, J. D. et al. (2001). The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 7504-7509.
28. Eckert, L. B., Repasky, G. A., Ulku, A. S., McFall, A., Zhou, H., Sartor, C. I. and Der, C. J. (2004). Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 64, 4585-4592.
29. Eckfeld, K., Hesson, L., Vos, M. D., Bièche, I., Latif, F. and Clark, G. J. (2004). RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 64, 8688-8693.
30. Endoh, M., Tamura, G., Honda, T., Homma, N., Terashima, M., Nishizuka, S. and Motoyama, T. (2005). RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer 93, 1395-1399.
31. E4F-dependent cell cycle arrest in G1. Mol. Cell. Biol. 21, 2956-2966.
32. Falvella, F. S., Manenti, G., Spinola, M., Pignatiello, C., Conti, B., Pastorino, U. and Dragani, T. A. (2006). Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 25, 3934-3938.
33. E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res. 64, 102-107.
34. Grote, H. J., Schmiemann, V., Geddert, H., Bocking, A., Kappes, R., Gabbert, H. E. and Sarbia, M. (2006). Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108, 129-134.
35. Guo, C., Tommasi, S., Liu, L., Yee, J. K., Dammann, R. and Pfeifer, G. P. (2007). RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 17, 700-705.
36. Halpain, S. and Dehmelt, L. (2006). The MAP1 family of microtubule-associated proteins. Genome Biol. 7, 224.
37. Hamilton, D. W., Lusher, M. E., Lindsey, J. C., Ellison, D. W. and Clifford, S. C. (2005). Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett. 227, 75-81.
38. Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., Hay, R. J., Minna, J. D. et al. (2002). Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21, 4345-4349.
39. Harvey, K. and Tapon, N. (2007). The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat. Rev. Cancer 7, 182-191.
40. Hesson, L., Dallol, A., Minna, J. D., Maher, E. R. and Latif, F. (2003). NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22, 947-954.
41. Hesson, L., Bièche, I., Krex, D., Criniere, E., Hoang-Xuan, K., Maher, E. R. and Latif, F. (2004). Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p31.3 region in gliomas. Oncogene 23, 2408-2419.
42. Hesson, L. B., Wilson, R., Morton, D., Adams, C., Walker, M., Maher, E. R. and Latif, F. (2005). CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24, 3987-3994.
43. Hesson, L. B., Cooper, W. N. and Latif, F. (2007). The role of RASSF1A methylation in cancer. Dis. Markers 23, 73-87.
44. Hogg, R. F., Honorio, S., Martinez, A., Agathanggelou, A., Dallol, A., Fullwood, P., Weichselbaum, R., Kuo, M. J., Maher, E. R. and Latif, F. (2002). Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J. Cancer 38, 1585-1592.
45. Honorio, S., Agathanggelou, A., Wernert, N., Rothe, M., Maher, E. R. and Latif, F. (2003). Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 22, 461-466.
46. Horiguchi, K., Tomizawa, Y., Tosaka, M., Ishiuchi, S., Kurihara, H., Mori, M. and Saito, N. (2003). Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 22, 7862-7865.
47. Huang, J., Wu, S., Barrera, J., Matthews, K. and Pan, D. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-434.
48. Hull, J., Rowlands, K., Lockhart, E., Sharland, M., Moore, C., Hanchard, N. and Kwiatkowski, D. P. (2004). Haplotype mapping of the bronchiolitis susceptibility locus near IL8. Hum. Genet. 114, 272-279.
49. Hwang, E., Ryu, K. S., Paakkonen, K., Guntert, F., Cheong, H. K., Lim, D. S., Lee, J. O., Jeon, Y. H. and Cheong, C. (2007). Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. Proc. Natl. Acad. Sci. USA 104, 9236-9241.
50. Irimia, M., Fraga, M. F., Sanchez-Cespedes, M. and Esteller, M. (2004). CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 23, 8695-8699.
51. Jeronimo, C., Henrique, R., Hoque, M. O., Mambo, E., Ribeiro, F. R., Varzim, G., Oliveira, J., Teixeira, M. R., Lopes, C. and Sidransky, D. (2004). A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 10, 8472-8478.
52. Johan, M. F., Bowen, D. T., Frew, M. E., Goodeve, A. C. and Reilly, J. T. (2005). Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 129, 60-65.
53. Katagiri, K., Maeda, A., Shimonaka, M. and Kinashi, T. (2003). RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat. Immunol. 4, 741-748.
54. Katoh, H., Shibata, T., Kokubu, A., Ojima, H., Fukayama, M., Kanai, Y. and Hirohashi, S. (2006). Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am. J. Pathol. 168, 1375-1384.
55. Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X. F., Seed, B. and Avruch, J. (2002). Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12, 253-265.
56. Kim, S. T., Lim, D.-S., Canman, C. E. and Kastan, M. B. (1999). Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem. 274, 37538-37543.
57. Kitagawa, D., Kajiho, H., Negishi, T., Ura, S., Watanabe, T., Wada, T., Ichijo, H., Katada, T. and Nishina, H. (2006). Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation. EMBO J. 25, 3286-3297.
58. Knudson, A. G., Jr (1971). Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad Sci. USA 68, 820-823.
59. Kuzmin, I., Gillespie, J. W., Protopopov, A., Geil, L., Dreijerink, K., Yang, Y., Vocke, C. D., Duh, F.-M., Zabarovsky, E., Minna, J. D. et al. (2002). The RASSF1A tumor suppressor gene is inactivated in protate tumors and suppresses growth of prostate carcinoma cell lines. Cancer Res. 62, 3498-3502.
60. Lambros, M. B., Fiegler, H., Jones, A., Gorman, F., Roylance, R. R., Carter, N. P. and Tomlinson, I. P. (2005). Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J. Pathol. 205, 29-40.
61. Lazcoz, P., Munoz, J., Nistal, M., Pestana, A., Encio, I. and Castresana, J. S. (2006). Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 6, 254.
62. Le Cam, L., Lacroix, M., Ciemerych, M. A., Sardet, C. and Sicinski, P. (2004). The E4F protein is required for mitotic progression during embryonic cell cycles. Mol. Cell. Biol. 24, 6467-6475.
63. Lerman, M. I. and Minna, J. D. (2000). The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res. 60, 6116-6133.
64. Levitt, N. C. and Hickson, I. D. (2002). Caretaker tumour suppressor genes that defend genome integrity. Trends Mol. Med. 8, 179-186.
65. Li, J., Zhang, Z., Dai, Z., Popkie, A. P., Plass, C., Morrison, C., Wang, Y. and You, M. (2003). RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia 5, 362-366.
66. Li, J., Wang, F., Protopopov, A., Malyukova, A., Kashuba, V., Minna, J. D., Lerman, M. I., Klein, G. and Zabarovsky, E. (2004). Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene. Oncogene 23, 5941-5949.
67. Liu, L., Amy, V., Liu, G. and McKeehan, W. L. (2002). Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5. Cancer Res. 65, 1830-1838.
68. Liu, L., Tommasi, S., Lee, D. H., Dammann, R. and Pfeifer, G. P. (2003). Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22, 8125-8136.
69. Liu, L., Broaddus, R. R., Yao, J. C., Xie, S., White, J. A., Wu, T. T., Hamilton, S. R. and Rashid, A. (2005). Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod. Pathol. 18, 1632-1640.
70. Liu, L., Baier, K., Dammann, R. and Pfeifer, G. P. (2007). The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex. Cell Cycle 6, 1663-1665.
71. Lusher, M. E., Lindsey, J. C., Latif, F., Pearson, A. D. J., Ellison, D. W. and Clifford, S. C. (2002). Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res. 62, 5906-5911.
72. Macheiner, D., Heller, G., Koppel, S., Bichler, C., Stattner, S., Ziegler, B., Kandioler, D., Wrba, E, Schulte-Hermann, R., Zöchbauer-Müller, S. et al. (2006). NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J. Hepatol. 45, 81-89.
73. Makarla, P. B., Saboorian, M. H., Ashfaq, R., Toyooka, K. O., Toyooka, S., Minna, J. D., Gazdar, A. F. and Schorge, J. O. (2005). Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res. 11, 5365-5369.
74. Marsit, C. J., Karagas, M. R., Schned, A. and Kelsey, K. T. (2006). Carcinogen exposure and epigenetic silencing in bladder cancer. Ann. N. Y. Acad. Sci. 1076, 810-821.
75. Mathe, E. (2004). RASSF1A, the new guardian of mitosis. Nat. Genet. 36, 117-118.
76. Michalowski, M. B., de Fraipont, R, Michelland, S., Entz-Werle, N., Grill, J., Pasquier, B., Favrot, M. C. and Plantaz, D. (2006). Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet. Cytogenet. 166, 74-81.
77. Miranda, E., Destro, A., Malesci, A., Balladore, E., Bianchi, F., Baryshnikova, E., Franchi, G., Morenghi, E., Laghi, L., Gennari, L. et al. (2006). Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br. J Cancer 95, 1101-1107.
78. Morris, M. R., Hesson, L. B., Wagner, K. J., Morgan, N. V., Astuti, D., Lees, R. D., Cooper, W. N., Lee, J., Gentle, D., Macdonald, F. et al. (2003). Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22, 6794-6801.
79. Murray, P. G., Qiu, G. H., Fu, L., Wailes, E. R., Srivastava, G., Heys, D., Agathanggelou, A., Latif, E. Grundy, R. G., Mann, J. R. et al. (2004). Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 23, 1326-1331.
80. Nakamura, N., Carney, J. A., Jin, L., Kajita, S., Pallares, J., Zhang, H., Qian, X., Sebo, T. J., Erickson, L. A. and Lloyd, R. V. (2005). RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab. Invest. 85, 1065-1075.
81. Nguyen, H. L, Gruber, D., Mcgraw, T., Sheetz, M. P. and Bulinski, J. C. (1998). Stabilization and functional modulation of microtubules by micrombule-associated protein 4. Biol. Bull. 194, 354-357.
82. Oh, H. J., Lee, K. K., Song, S. J., An, M. S., Song, M. S., Lee, J. H., Im, C. R., Lee, J. O., Yonehara, S. and Lim, D.-S. (2006). Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 66, 2562-2569.
83. Oliveira, C., Velho, S., Domingo, E., Preto, A., Hofstra, R. M., Hamelin, R., Yamamoto, H., Seruca, R. and Schwartz, S., Jr (2005). Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 24, 7630-7634.
84. O'Neill, E. E., Matallanas, D. and Kolch, W. (2005). Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res. 65, 5485-5487.
85. Orbán-Németh, Z., Simader, H., Badurek, S., Tranciková, A. and Propst, F. (2006). Differences in the regulation of microtubule stability by the pro-rich region variants of microtubule-associated protein 4. FEBS Lett. 580, 3505-3510.
86. Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X. F., Dammann, R., Pfeifer, G. P. and Avruch, J. (2002). The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Norel. Oncogene 21, 1381-1390.
87. Pan, Z. G., Kashuba, V. I., Liu, X. Q., Shoo, J. Y., Zhang, R. H., Jiang, J. H., Guo, C., Zabarovsky, E., Ernberg, I. and Zeng, Y. X. (2005). High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol. Ther. 4, 1116-1122.
88. Peters, J. M. (2002). The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell 9, 931-943.
89. Pfeffer, G. F. and Dammann, R. (2005). Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry Mosc. 70, 576-583.
90. Polesello, C., Huelsmann, S., Brown, N. H. and Tapon, N. (2006). The Drosophila RASSF1A homolog antagonizes the hippo pathway. Curr. Biol. 16, 2459-2465.
91. Praskova, M., Khokhlatchev, A., Ortiz-Vega, S. and Avruch, J. (2004). Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins RASSF1 and NORE1, and by Ras. Biochem. J. 381, 453-462.
92. Rabizadeh, S., Xavier, R. J., Ishiguro, K., Bernabeortiz, J., Lopez-Ilasaca, M., Khokhlatchev, A., Mollahan, P., Pfeifer, G. P., Avruch, J. and Seed, B. (2004). The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J. Biol. Chem. 279, 29247-29254.
93. Rodriguez-Viciana, P., Sabatier, C. and McCormick, F. (2004). Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24, 4943-4954.
94. Rong, R., Jin, W., Zhang, J., Sheikh, M. S. and Huang, Y. (2004). Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 23, 8216-8230.
95. Saavedra, H. I., Knauf, J. A., Shirokawa, J. M., Wang, J., Ouyang, B., Elisei, R., Stambrook, P. J. and Fagin, J. A. (2000). The RAS oncogene induces genomic instability in thyroid PCCL3 cell via the MAPK pathway. Oncogene 19, 3948-3954.
96. Safar, A. M., Spencer, H., III, Su, X., Coffey, M., Cooney, C. A., Ratnasinghe, L. D., Hutchins, L. F. and Fan, C. Y. (2005). Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin. Cancer Res. 11, 4400-4405.
97. Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang-Vu, C. and Dammann, R. (2006). CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16, 633-642.
98. Scheel, H. and Hofmann, K. (2003). A novel interaction motif, SARAH, connects three classes of tumor suppressor. Curr Biol. 13, R899-R900.
99. Sharpe, J. C., Arnoult, D. and Youle, R. J. (2004). Control of mitochondrial permeability by Bcl-2 family members. Biochim. Biophys. Acta 1644, 107-113.
100. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168.
101. Shinozaid, M., Hoon, D. S., Giuliano, A. E., Hansen, N. M., Wang, H. J., Turner, R. and Taback, B. (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res. 11, 2156-2162.
102. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R. and White, M. A. (2002). The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 22, 4309-4318.
103. Song, M. S., Song, S. J., Ayad, N. G., Chang, J. S., Lee, J. H., Hong, H. K., Lee, H., Choi, N., Kim, J., Kim, H. et al. (2004). The tumor suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc2O complex. Nat. Cell Biol. 6, 129-137.
104. Song, M. S., Chang, J. S., Song, S. J., Yang, T. H., Lee, H. and Lim, D.-S. (2005). The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles. J. Biol. Chem. 280, 3920-3927.
105. Spugnardi, M., Tommasi, S., Dammann, R., Pfeifer, G. P. and Hoon, D. S. (2003). Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63, 1639-1643.
106. St John, M. A., Tao, W., Fei, X., Fukumoto, R., Carcangiu, M. L., Brownstein, D. G., Parlow, A. F., McGrath, J. and Xu, T. (1999). Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian turnouts and pituitary dysfunction. Nat. Genet. 21, 182-186.
107. Tan, K. O., Tan, K. M., Chan, S. L., Yee, K. S., Bevort, M., Ang, K. C. and Yu, V. C. (2001). MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J. Biol. Chem. 276, 2802-2807.
108. Tan, S. H., Ida, H., Goh, B. C., Hsieh, W., Loh, M. and Ito, Y. (2006). Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Res. 26, 4287-4292.
109. Tao, W., Zhang, S., Turenchalk, G. S., Stewart, R. A., St John, M. A., Chen, W. and Xu, T. (1999). Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat. Genet. 21, 177-181.
110. Teodoridis, J. M., Hall, J., Marsh, S., Kannall, H. D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H. L., Strathdee, G. et al. (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65, 8961-8967.
111. Tischoff, I., Markwarth, A., Witzigmann, H., Uhlmann, D., Hauss, J., Mirmohammadsadegh, A., Wittekind, C., Hengge, U. R. and Tannapfel, A. (2005). Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int. J. Cancer 115, 684-689.
112. Togel, M., Wiche, G. and Propst, E. (1998). Novel features of the light chain of microtubude-associated protein MAP1B: microtubule stabilization, self interaction, actin filament binding, and regulation by the heavy chain. J. Cell Biol. 143, 695-707.
113. Tomizawa, Y., Kohno, T., Kondo, H., Otsuka, A., Nishioka, M., Niki, T., Yamada, T., Maeshima, A., Yoshimura, K., Saito, R. et al. (2002). Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin. Cancer Res. 8, 2362-2368.
114. Tommasi, S., Dammann, R., Jin, S. G., Zhang, X. F., Avruch, J. and Pfeifer, G. P. (2002). RASSF3 and NORE1: identification and cloning of two homologues of the putative tumor suppressor gene RASSF1. Oncogene 21, 2713-2720.
115. Tommasi, S., Dammann, R., Zhang, Z., Wang, Y., Liu, L., Tsark, W. M., Wilczynski, S. P., Li, J., You, M. and Pfeifer, G. P. (2005). Tumor susceptibility of RASSF1A knockout mice. Cancer Res. 65, 92-98.
116. Urn, S., Nishina, H., Gotoh, Y. and Katada, T. (2007). Activation of the JNK pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis. Mol. Cell. Biol. 27, 5514-5522.
117. van der Weyden, L., Tachibana, K. K., Gonzalez, M. A., Adams, D. J., Ng, B. L., Petty, R., Venkitaraman, A. R., Arends, M. J. and Bradley, A. (2005). The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol. Cell. Biol. 25, 8356-8367.
118. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruine, A. P., Arends, J. W., van den Brandt, P. A., de Goeij, A. F. and Herman, J. G. (2002). K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21, 3792-3795.
119. Vavvas, D., Li, X., Avruch, J. and Zhang, X. F. (1998). Identification of Norel as a potential Ras effector. J. Biol. Chem. 273, 5439-5442.
120. Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J. and Clark, G. J. (2000). Ras uses the novel tumor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275, 35669-35672.
121. Vos, M. D., Ellis, C. A., Elam, C., Ulku, A. S., Taylor, B. J. and Clark, G. J. (2003a). RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 278, 28045-28051.
122. Vos, M. D., Martinez, A., Ellis, C. A., Vallecorsa, T. and Clark, G. J. (2003b). The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J. Biol. Chem. 278, 21938-21943.
123. Vos, M. D., Martinez, A., Elam, C., Dallol, A., Taylor, B. J., Latif, F. and Clark, G. J. (2004). A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 64, 4244-4250.
124. Vos, M. D., Dallol, A., Eckfeld, K., Allen, N. P. C., Donninger, H., Hesson, L. B., Calvisi, D., Latif, F. and Clark, G. J. (2006). The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. 281, 4557-4563.
125. Wagner, K. J., Cooper, W. N., Grundy, R. G., Caldwell, G., Jones, C., Wadey, R. B., Morton, D., Schofield, P. N., Reik, W., Latif, F. et al. (2002). Frequent RASSF1A tumor suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 21, 7277-7282.
126. Wassmann, K. and Benezra, R. (2001). Mitotic checkpoints: from yeast to cancer. Curr. Opin. Genet. Dev. 11, 83-90.
127. 2-kinase pathway and inhibits cell cycle progression. Cancer Res. 65, 3682-3690.
128. Wong, M. L., Tao, Q., Fu, L., Wong, K. Y., Qiu, G. H., Law, F. B., Tin, P. C., Cheung, W. L., Lee, P. Y., Tang, J. C. et al. (2006). Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Int. J. Oncol. 28, 767-773.
129. Yabuta, N., Fujii, T., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Nishiguchi, H., Endo, Y., Toji, S., Tanaka, H., Nishimune, Y. et al. (2000). Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 63, 263-270.
130. Yeo, W., Wong, W. L., Wong, N., Law, B. K., Tse, G. M. and Zhong, S. (2005). High frequency ofpromoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 37, 125-130.
131. Yoon, J.-H., Dammann, R. and Pfeifer, G. F. (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217.
132. Yu, H. (2007). Cdc20: a WD40 activator for a cell cycle degradation machine. Mol. Cell 27, 3-16.
133. Yu,, M. Y., Tong, J. H., Chan, P. K., Lee, T. L., Chan, M. W., Chan, A. W., Lo, K. W. and To, K. F. (2003). Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int. J. Cancer 105, 204-209.
134. Zachariae, W. and Nasmyth, K. (1999). Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev. 13, 2039-2058.